Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 1 Glioblastoma 1

Interventions

Temozolomide 39 Radiotherapy 18 Lomustine 12 Bevacizumab 11 Carmustine 8 Radiation 7 Procarbazine 4 Magnetic Resonance Spectroscopy 4 Surgical Procedures, Operative 3 pembrolizumab 2 depatuxizumab mafodotin 2 Tf-CRM107 2 Specimen Handling 2 Radiotherapy, Intensity-Modulated 2 Drug Therapy 2 Dihematoporphyrin Ether 2 DNA Methylation 2 Carboplatin 2 ABT-414 2 trans-sodium crocetinate 1 tofacitinib 1 sargramostim 1 rindopepimut 1 niraparib 1 marizomib 1 enzastaurin 1 edotecarin 1 contrast agent BR1 1 cediranib 1 carmustine, poliferprosan 20 drug combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Glioblastoma × enzastaurin × Clear all

NCT00295815 2019-09-12

Enzastaurin Versus Lomustine in Glioblastoma

Eli Lilly and Company

Phase 3 Completed

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡